Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What thoughts does the collective MB have on the possibilities of either partnering or BIGGER PARTNERS B/O sniffing around now that some of the cat is sticking out of the bag?? My thinking is BP speculations will be all over AVXL looking for any new data . Will they be compelled to move or just wait? If they do move early are we talking about most likely buying AVXL outright or other sharing deals?
"Checkmate" ..."Ortiz"
boi568
georgejji
xodcode,
Wait a few (hrs) while the power of this PR sinks in. This , by far, the very best news any AVXL patient-family member or share holder could have prayed for. It may take a while to sink in for some. We can finally say w/ a confidence level approaching certainty that...WGT.
D-Mike
We’ve seen this movie before.
WOW AGAIN...
“This publication is a confirmation of the scientific depth of Anavex’s upstream SIGMAR1 platform, which gives hope to the Alzheimer’s disease community, especially for the patients, families and caregivers who fight everyday against this devastating disease for a potential disease-modifying drug candidate with a once daily oral preventive strategy. We also look forward to presenting in an upcoming major publication the complete dataset of the Phase 2b/3 Alzheimer’s disease trial of ANAVEX®2-73 (blarcamesine), a potential next-generation precision medicine convenient once daily oral Alzheimer’s disease treatment,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "We are also on track within our neurodevelopmental precision medicine Rett syndrome program to release top-line data of ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the current quarter of 2023.”
plexrec
" presenting in an upcoming major publication the complete dataset of the Phase 2b/3 Alzheimer’s disease trial of ANAVEX®2-73 (blarcamesine), a potential next-generation"----no way would they be presenting if news was not very positive--same for Excellence data--TGD finally giving some clues as what's coming next--he knows WGT !!!!!!!
tredenwater2
Things that make you go hmmmm.
why would I want the distraction of CTAD, especially during heavy negotiations.
We are reminded that..."silence is STILL NOT and effective communication strategy".
boi568:
those ex-FDA staffers has expertise in designing preclinical tests, not anything we would hear about
Knock off the arrogant, condescending... B.S.
that’s pretty amazing considering the competition
Anavex...(we know) is a event CTAD sponsor (CODE FOR $$$). It would not be a GIANT LEAP of Faith to expect some form of surprise AD AVXL PR .
IMO, whatever caused the massive downdraft yesterday was an obvious, organized effort. The SP loss yesterday was not any kind of normal -typical event. Someone or thing made the SP happen in an organized planned manner. AVXL will recover when the/a solution is applied. There was a cause for that drop. Not attributed to an AVXL result or clinical failure. We'll see...keep the faith.
Wow, what are we, days away from take off? Get ready folks he is for real.. Tell em Monks!
BakedLangostino...lots of opinions ... for someone who just appeared you present multiple (claimed informed) opinions . Get in line, most here are informed position holders.
It's easy to create a pro vs con list for everything: it's all speculation. Here's what I believe:
If Sigma-1 holds the key to prophylactic treatment, or at the very least surpasses current schizophrenia drugs, that's going to unlock the true value. Schizophrenia and A371 is the market I care about. Blarcamesine is more or less irrelevant in the short term.
tredenwater
Im giving until Dec 31 2023 to receive Rett Syndrome TLR before I start my “shareholder concern campaign” against management.
Tred
Comments anyone ???
interim share price of a manipulated clinical stage biotech is immaterial
"Biogen to Present New Data at the Clinical Trials"--and what is our GD doing ????
Thanks hnbadger1, so far, so good today when access as normally have for long time...will make note of this clue...
upper right hand corner of the box.. ei post 40867.. it reverts it classic.
test...10/18...not AB-E-NORMAL TODAY ...YET
test...pls fix this display
georgejji[quote Expect great news regarding AVXL by or before Wednesday this week.][/quote]
EXCELLENT...WELL DONE, will stand by .
Surprise this week coming for AVXL.
Expect GREAT NEWS THIS WEEK regarding AVXL.
The second quote indicates it should be published within a week, the 60 days to take effect.
Doing a quick review of AVXL Quality Management systems-docs and find no ISO certification listing-record. The attached linked paper is comprehensive (touches all the bases) and well written but is silent on any ISO international (QMS) assessment-Certification . An ISO (Quality Management System certification) by a WW ISO systems registrar may not be typical for a firm like AVXL (at pre-production level), but it would be a reasonable/expected goal (near future management -leadership goal).
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.issgovernance.com/file/duediligence/ISS-Information-Security-Whitepaper-2022.pdf
IMO...it's time to go kick some axx.
HAVE A NICE DAY...
Dear journals: stop hoarding our papers
https://www.nature.com/articles/d41586-023-03196-y
Good luck and GOD bless,
There's a step-by-step process that every pre-revenue biotech must follow to achieve success. It's not easy. But Dr. Missling has succeeded with all three P1, P2 and P3 trials for adult Rett. We are now waiting for the last piece of the puzzle - Rett Excellence P3 results for children ages 5 - 17. It's important that they get all of the numbers right or the FDA will reject their application.
crismissing, thanks for the update, sorry about the bitching and moaning, fix whatever is broken, ASAP.
Dr.M., send us a direct message of support...ASAP...now , would be great..
This is not off topic - it is an illustration of how subjective and ignorant the medical community is.
jonj325
You would think Reduction in Brain Atrophy would be a great CTAD topic.
Could have been a good headline.
Thx, appreciate your reply.
was told by the company a few months ago that they have asked new employees to not put their career change on their LinkedIn profile. It is part of their stealth strategy. They have approximately 50 - 60 employees now and interviewing all the time. Having a sales manager on board is probably correct at this point in time.
tradeher
" most individuals with Down syndrome have abnormal clumps of amyloid"--2-73 would definitely be a great "fix" for these people !